Literature DB >> 18036650

Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement.

Hidenori Yokoi1, Oksoon H Choi, Walter Hubbard, Hyun-Sil Lee, Brendan J Canning, Hyun H Lee, Seung-Duk Ryu, Stephan von Gunten, Carol A Bickel, Sherry A Hudson, Donald W Macglashan, Bruce S Bochner.   

Abstract

BACKGROUND: Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of glycan-binding inhibitory receptors, and among them, Siglec-8 is selectively expressed on human eosinophils, basophils, and mast cells. On eosinophils, Siglec-8 engagement induces apoptosis, but its function on mast cells is unknown.
OBJECTIVE: We sought to study the effect of Siglec-8 engagement on human mast cell survival and mediator release responses.
METHODS: Human mast cells were generated from CD34+ precursors. Apoptosis was studied by using flow cytometry. Mast cell mediator release or human lung airway smooth muscle contraction was initiated by FcepsilonRI cross-linking with or without preincubation with Siglec-8 or control antibodies, and release of mediators was analyzed along with Ca++ flux. RBL-2H3 cells transfected with normal and mutated forms of Siglec-8 were used to study how Siglec-8 engagement alters mediator release.
RESULTS: Siglec-8 engagement failed to induce human mast cell apoptosis. However, preincubation with Siglec-8 mAbs significantly (P < .05) inhibited FcepsilonRI-dependent histamine and prostaglandin D(2) release, Ca++ flux, and anti-IgE-evoked contractions of human bronchial rings. In contrast, release of IL-8 was not inhibited. Siglec-8 ligation was also shown to inhibit beta-hexosaminidase release and Ca++ flux triggered through FcepsilonRI in RBL-2H3 cells transfected with full-length human Siglec-8 but not in cells transfected with Siglec-8 containing a tyrosine to phenylalanine point mutation in the membrane-proximal immunoreceptor tyrosine-based inhibitory motif domain.
CONCLUSION: These data represent the first reported inhibitory effects of Siglec engagement on human mast cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036650     DOI: 10.1016/j.jaci.2007.10.004

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  59 in total

1.  Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression.

Authors:  Sherry A Hudson; Harald Herrmann; Jian Du; Paul Cox; El-Bdaoui Haddad; Barbara Butler; Paul R Crocker; Steven J Ackerman; Peter Valent; Bruce S Bochner
Journal:  J Clin Immunol       Date:  2011-09-22       Impact factor: 8.317

2.  Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8.

Authors:  Ho Jeong Na; Robert G Hamilton; Amy D Klion; Bruce S Bochner
Journal:  J Immunol Methods       Date:  2012-06-06       Impact factor: 2.303

Review 3.  Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.

Authors:  Robert P Schleimer; Ronald L Schnaar; Bruce S Bochner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2016-02

4.  Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8.

Authors:  Johannes M Pröpster; Fan Yang; Said Rabbani; Beat Ernst; Frédéric H-T Allain; Mario Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

5.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

6.  Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.

Authors:  Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Bruce S Bochner; Henrik S Rasmussen; Kathryn Peterson; Christopher Bebbington; Nenad Tomasevic
Journal:  JCI Insight       Date:  2019-10-03

Review 7.  Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.

Authors:  B S Bochner
Journal:  Clin Exp Allergy       Date:  2009-03       Impact factor: 5.018

8.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

Review 9.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 10.  Advances in mechanisms of asthma, allergy, and immunology in 2008.

Authors:  Joshua A Boyce; David Broide; Kenji Matsumoto; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2009-03       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.